A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do not undergo sentinel lymph node biopsy (SLNB).
2025
Blocking an enzyme may improve melanoma immunotherapy outcomes
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) discovered that an enzyme called HPGDS (expressed in a specific subset of macrophages), plays a key role in immunotherapy resistance. Blocking HPGDS may be a new way to overcome immunotherapy resistance in melanoma patients and potentially in other tumors facing similar challenges. The results of this study were published in Cancer Discovery.
Breakthrough paves way for predicting melanoma patient response to treatment
A major step forward has been made in predicting how well melanoma patients would respond to treatment, thanks to world-leading University of Otago – ?t?kou Whakaihu Waka research.
Cancer-fighting implant shows promise in treating melanoma, pancreatic and colorectal tumors
Cancer-fighting implant shows promise in treating melanoma, pancreatic and colorectal tumors